Evidence map›Paper›PMID 38232993›Full record

ArticleBMJ global health2024

Development of a cross-sectoral antimicrobial resistance capability assessment framework.

Angeline S Ferdinand, Callum McEwan, Chantel Lin, Kassandra Betham, Karishma Kandan, Gilam Tamolsaian, Barry Pugeva, Joanna McKenzie, Glenn Browning, James Gilkerson and 11 more

Abstract read
In one paragraph

Article in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Multivalent Glycopolymer Design Unlocks Antimicrobial Activity of 2-Deoxyglucose.Angewandte Chemie (International ed. in English) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Angeline S FerdinandWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia a.ferdinand@unimelb.edu.au.ORCID 0000-0002-4816-5539
Callum McEwanWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-9415-2483
Chantel LinWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.
Kassandra BethamWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.
Karishma KandanWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.
Gilam TamolsaianBurnet Institute, Melbourne, Victoria, Australia.
Barry PugevaBurnet Institute, Melbourne, Victoria, Australia.
Joanna McKenzieMolecular Epidemiology Laboratory, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
Glenn BrowningAsia-Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Melbourne, Victoria, Australia.
James GilkersonAsia-Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Melbourne, Victoria, Australia.
Mauricio CoppoAsia-Pacific Centre for Animal Health, Melbourne Veterinary School, The University of Melbourne, Melbourne, Victoria, Australia.
Rodney JamesDoherty Institute, Melbourne, Victoria, Australia.
Trisha PeelDepartment of Infectious Diseases, Monash University and Alfred Health, Melbourne, Victoria, Australia.
Steph LevyBurnet Institute, Melbourne, Victoria, Australia.
Nicola TownellInfectious Disease Department, Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia.
Adam JenneyDepartment of Infectious Diseases, Monash University, Clayton, Victoria, Australia.
Andrew StewardsonDepartment of Infectious Diseases, Alfred Health, Melbourne, Victoria, Australia.
Donna CameronWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.
Alison MacintyreNossal Institute for Global Health, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Kirsty BuisingWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.
Benjamin P HowdenWHO Collaborating Centre for Antimicrobial Resistance, Doherty Institute, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is an urgent and growing global health concern, and a clear understanding of existing capacities to address AMR, particularly in low-income and middle-income countries (LMICs), is needed to inform national priorities, investment targets and development activities. Across LMICs, there are limited data regarding existing mechanisms to address AMR, including national AMR policies, current infection prevention and antimicrobial prescribing practices, antimicrobial use in animals, and microbiological testing capacity for AMR. Despite the development of numerous individual tools designed to inform policy formulation and implementation or surveillance interventions to address AMR, there is an unmet need for easy-to-use instruments that together provide a detailed overview of AMR policy, practice and capacity. This paper describes the development of a framework comprising five assessment tools which provide a detailed assessment of country capacity to address AMR within both the human and animal health sectors. The framework is flexible to meet the needs of implementers, as tools can be used separately to assess the capacity of individual institutions or as a whole to align priority-setting and capacity-building with AMR National Action Plans (NAPs) or national policies. Development of the tools was conducted by a multidisciplinary team across three phases: (1) review of existing tools; (2) adaptation of existing tools; and (3) piloting, refinement and finalisation. The framework may be best used by projects which aim to build capacity and foster cross-sectoral collaborations towards the surveillance of AMR, and by LMICs wishing to conduct their own assessments to better understand capacity and capabilities to inform future investments or the implementation of NAPs for AMR.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsAnimalsCapacity BuildingDrug Resistance, BacterialHumansPolicyAnti-Bacterial AgentsAnti-Infective AgentsHealth systems evaluationInfections, diseases, disorders, injuriesMedical microbiologyPublic Health

Identifiers

PMID38232993
PMCPMC10806917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.